Citations

Showing 10 of 108135 citations.

Repeated Cross-sectional Surveys of Burnout, Distress, and Depression among Anesthesiology Residents and First-year Graduates
Macario, Alex, Zhou, Yan , Culley, Deborah J. , Keegan, Mark T. , Sun, Huaping , Sun, Huaping, Warner, David O.

Mayo Clinic

Anesthesiology | June 5, 2019 | Volume: 131 | Issue: 3 | Pages: 668-677

10.1097/aln.0000000000002777 | PMID 31166235 Get It

Abstract Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New Background This repeated cross-sectional survey study was conducted to determine the prevalence of, and factors associated with, burnout, distress, and depression among anesthesiology residents and first-year graduates. We hypothesized that heavy workload and student debt burden were associated with a higher risk of physician burnout, distress, and depression, and that perception of having adequate workplace resources, work–life balance, and social support were associated with a lower risk. Methods Physicians beginning U.S. anesthesiology residency between 2013 and 2016 were invited to take online surveys annually from their clinical anesthesia year 1 to 1 yr after residency graduation. The Maslach Burnout Inventory, the Physician Well-Being Index, and the Harvard Department of Psychiatry/National Depression Screening Day Scale were used to measure burnout, distress, and depression, respectively. Logistic regression analyses were conducted to examine whether self-reported demographics, personal, and professional factors were associated with the risk of burnout, distress, and depression. Results The response rate was 36% (5,295 of 14,529). The prevalence of burnout, distress, and depression was 51% (2,531 of 4,966), 32% (1,575 of 4,941), and 12% (565 of 4,840), respectively. Factors associated with a lower risk of all three outcomes included respondents’ perceived workplace resource availability, (odds ratio = 0.51 [95% CI, 0.45 to 0.57] for burnout; 0.51 [95% CI, 0.45 to 0.56] for distress; 0.52 [95% CI, 0.45 to 0.60] for depression) and perceived ability to maintain work–life balance (0.61 [95% CI, 0.56 to 0.67] for burnout; 0.50 [95% CI, 0.46 to 0.55] for distress; 0.58 [95% CI, 0.51 to 0.65] for depression). A greater number of hours worked per week and a higher amount of student debt were associated with a higher risk of distress and depression, but not burnout. Conclusions Burnout, distress, and depression are notable among anesthesiology residents. Perceived institutional support, work–life balance, strength of social support, workload, and student debt impact physician well-being.
The American Board of Anesthesiology’s Staged Examination System and Performance on the Written Certification Examination After Residency
Macario, Alex, Martin, Donald E., Zhou, Yan , Sun, Huaping , Rathmell, James P. , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | June 5, 2019 | Volume: 129 | Issue: 5 | Pages: e159-e162

10.1213/ane.0000000000004250 | PMID 31613812 Get It

This study compared anesthesiology residency graduates’ written certification examination performance before and after the American Board of Anesthesiology (ABA) introduced the staged examination system. After equating test scores using common test items, the first 2 cohorts (2013, 2014) in the staged system scored 7.1 points and 8.3 points higher than the 2011 baseline cohort in the former examination system. The 2013 and 2014 cohorts’ pass rates (94.2% and 95.9%) were also higher than the 2011 and 2012 cohorts (91.9% and 92.6%) if a common standard had been applied. The staged examination system may be associated with improved knowledge of anesthesiology graduates.
Congenital myopathies in the adult neuromuscular clinic
Nicolau, Stefan , Liewluck, Teerin , Tracy, Jennifer A., Laughlin, Ruple S. , Milone, Margherita , Liewluck, T , Nicolau, Stefan

Mayo Clinic

Neurology Genetics | June 5, 2019 | Volume: 5 | Issue: 4 | Pages: No page available

10.1212/nxg.0000000000000341 | PMID 31321302 Get It

A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer
Sonbol, Mohamad Bassam , Benkhadra, Raed, Firwana, Belal , Walden, Daniel J., Mody, Kabir , Murad, M. Hassan , Ahn, Daniel H. , Bekaii‐Saab, Tanios , Walden, Daniel , Hubbard, Joleen M. , Murad, M Hassan , Sonbol, Mohamad B , Bekaii-Saab, Tanios S , Wang, Zhen

Mayo Clinic

The Oncologist | June 4, 2019 | Volume: 24 | Issue: 9 | Pages: 1174-1179

10.1634/theoncologist.2019-0189 | PMID 31164455 Get It

Abstract Background Regorafenib at different dosing strategies and TAS-102 are treatment options for refractory metastatic colorectal cancer (mCRC). We aimed to evaluate the comparative effectiveness evidence supporting these different strategies. Materials and Methods We searched different databases for randomized controlled trials evaluating TAS-102 or regorafenib in patients with refractory mCRC who failed prior oxaliplatin, irinotecan, and fluoropyrimidine. Outcomes of interest included overall survival (OS) and progression-free survival (PFS). The overall effect was pooled using the DerSimonian random effects model. We conducted network meta-analysis based on White's multivariate meta-regression to pool evidence from direct and indirect comparisons. Results Six trials at low risk of bias (2,445 patients) were included. Direct comparisons showed that Rego 160 and TAS-102 as monotherapy were superior to best-supportive care (BSC) in terms of PFS (Rego 160: hazard ratio [HR], 0.4; 95% confidence ratio [CI], 0.26–0.63; TAS-102: HR, 0.46 CI, 0.40–0.52) and OS (Rego 160: HR, 0.67; CI, 0.48–0.93; TAS-102: HR, 0.67; CI, 0.57–0.80). Network analysis showed no statistically difference in PFS or OS between Rego 160 and TAS-102. Rego 80+ was superior to BSC in terms of OS (HR, 0.44; CI, 0.23–0.84) and PFS (HR, 0.37; CI, 0.21–0.66). Rego 80+ was associated with statistically nonsignificant improvement in OS and PFS compared with TAS-102 and Rego 160. Conclusion Regorafenib 160 and TAS-102 appear to have similar efficacy. Rego 80+ is shown to be superior to BSC. A trend for improved OS was observed with Rego 80+ versus Rego 160 or TAS 102. Implications for Practice Regorafenib at a dose of 160 mg and TAS-102 appear to have similar efficacy in patients with refractory metastatic colorectal cancer. Regorafenib with a dose escalation strategy is superior to best-supportive care. Given its tolerability and the observed trend in survival benefit compared with regorafenib 160, dose escalation strategy of regorafenib (80+) may be the preferred option in this setting.
Conversations About Financial Issues in Routine Oncology Practices: A Multicenter Study
Warsame, Rahma , Kennedy, Cassie C. , Kumbamu, Ashok , Fernandez, Cara, Kimball, Brittany , Leppin, Aaron L. , O’Byrne, Thomas J., Jatoi, Aminah , Lenz, Heinz‐Josef , Tilburt, Jon C. , O'Byrne, Thomas, Kimball, Brittany C , Kennedy, Cassie C , Branda, Megan E.

Mayo Clinic

Journal of Oncology Practice | June 4, 2019 | Volume: 15 | Issue: 8 | Pages: e690-e703

10.1200/jop.18.00618 | PMID 31162996 Get It

PURPOSE: To describe the frequency, content, dynamics, and patterns of cost conversations in academic medical oncology across tumor types. PATIENTS AND METHODS: We reviewed 529 audio recordings between May 3, 2012, to September 23, 2014, from a prospective three-site communication study in which patients at any stage of management for any solid tumor malignancy were seen in routine oncology appointments. Recordings were deidentified, transcribed, and flagged for any mention of cost. We coded encounters and used qualitative thematic analysis. RESULTS: Financial issues were discussed in 151 (28%) of 529 recordings. Conversations lasted shorter than 2 minutes on average. Patients/caregivers raised a majority of discussions (106 of 151), and 40% of cost concerns raised by patients/caregivers were not verbally acknowledged by clinicians. Social service referrals were made only six times. Themes from content analysis were related to insurance eligibility/process, work insecurity, cost of drugs, cost used as tool to influence medical decision making, health care–specific costs, and basic needs. Financial concerns influenced oncology work processes via test or medication coverage denials, creating paperwork for clinicians, potentially influencing patient involvement in trials, and leading to medication self-rationing or similar behaviors. Typically, financial concerns were associated with negative emotions. CONCLUSION: Financial issues were raised in approximately one in four academic oncology visits. These brief conversations were usually initiated by patients/caregivers, went frequently unaddressed by clinicians, and seemed to influence medical decision making and work processes and contribute to distress. Themes identified shed light on the kinds of gaps that must be addressed to help patients with cancer cope with the rising cost of care.
Prolonged Hypercupremia after Laparoscopic Vertical Sleeve Gastrectomy Successfully Treated with Oral Zinc
Koch, Timothy R. , Zubowicz, Elizabeth A., Gross, John B.

Mayo Clinic

Case Reports in Gastrointestinal Medicine | June 4, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-4

10.1155/2019/8175376 | PMID 31275668 Get It

A 30-year-old female underwent vertical sleeve gastrectomy. Postoperatively, hypercupremia and elevated ceruloplasmin were identified. Further testing revealed normal blood levels of transaminases, alkaline phosphatase, and albumin. She stopped ingestion of multivitamins, began a copper-free multivitamin, and then began a low copper diet, but with no improvement in hypercupremia. Protein electrophoresis was normal with no M-spike. Urinary copper excretion was normal at 0.24 micromol/24 hours (normal: < 0.55), and there were no Kayser-Fleischer rings on slit lamp examination. Two years postoperatively, she lost 44% of excess preoperative weight and she began zinc sulfate before meals twice daily (115 mg elemental Zinc/day). At 2 months and 8 months later, plasma copper and ceruloplasmin had essentially normalized. Increased production of ceruloplasmin could have been a response to significant weight loss or the presence of nonalcoholic steatohepatitis. The mechanism of zinc’s beneficial effect is uncertain but may be related to suppressing hepatic synthesis of or secretion of ceruloplasmin.
Correspondence
Duchalais, Émilie , Larson, David W.

Mayo Clinic

British Journal of Surgery | June 4, 2019 | Volume: 106 | Issue: 7 | Pages: 950-951

10.1002/bjs.11202 | PMID 31162660 Get It

Coccidioidomycosis Detection Using Targeted Plasma and Urine Metabolic Profiling
Jasbi, Paniz , Mitchell, Natalie M., Grys, Thomas E. , Wei, Yiping , Liu, Li , Lake, Douglas F. , Gu, Haiwei , Gu, Haiwei , Grys, Thomas E , Shi, Xiaojian

Mayo Clinic

Journal of Proteome Research | June 4, 2019 | Volume: 18 | Issue: 7 | Pages: 2791-2802

10.1021/acs.jproteome.9b00100 | PMID 31244214 Get It

Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus–Associated Oropharynx Squamous Cell Carcinoma
Price, Katharine A. , Moore, Eric J. , Patel, Samir H. , Hinni, Michael L., García, Joaquín J. , Graner, Darlene E., Foster, Nathan R. , Ginos, Brenda, Neben-Wittich, M.A. , Garces, Yolanda I. , Chintakuntlawar, Ashish V. , Olsen, Kerry D., Abel, Kathryn M. Van , Kasperbauer, Jan L. , Janus, Jeffrey R. , Waddle, Mark R. , Miller, Robert C. , Shiraishi, Satomi , Foote, Robert L. , Neben-Wittich, Michelle, Waddle, Mark, Van Abel, Kathryn M , Chintakuntlawar, Ashish V , Daniel, J. , Price, Daniel L. , Shiraishi, Satomi

Mayo Clinic

Journal of Clinical Oncology | June 4, 2019 | Volume: 37 | Issue: 22 | Pages: 1909-1918

10.1200/jco.19.00463 | PMID 31163012 Get It

PURPOSE The purpose of this study was to determine if dose de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma could maintain historical rates for disease control while reducing toxicity and preserving swallow function and quality of life (QOL). PATIENTS AND METHODS MC1273 was a single-arm phase II trial testing an aggressive course of RT de-escalation after surgery. Eligibility criteria included patients with p16-positive oropharyngeal squamous cell carcinoma, smoking history of 10 pack-years or less, and negative margins. Cohort A (intermediate risk) received 30 Gy delivered in 1.5-Gy fractions twice per day over 2 weeks along with 15 mg/m 2 docetaxel once per week. Cohort B included patients with extranodal extension who received the same treatment plus a simultaneous integrated boost to nodal levels with extranodal extension to 36 Gy in 1.8-Gy fractions twice per day. The primary end point was locoregional tumor control at 2 years. Secondary end points included 2-year progression-free survival, overall survival, toxicity, swallow function, and patient-reported QOL. RESULTS Accrual was from September 2013 to June 2016 (N = 80; cohort A, n = 37; cohort B, n = 43). Median follow-up was 36 months, with a minimum follow-up of 25 months. The 2-year locoregional tumor control rate was 96.2%, with progression-free survival of 91.1% and overall survival of 98.7%. Rates of grade 3 or worse toxicity at pre-RT and 1 and 2 years post-RT were 2.5%, 0%, and 0%. Swallowing function improved slightly between pre-RT and 12 months post-RT, with one patient requiring temporary feeding tube placement. CONCLUSION Aggressive RT de-escalation resulted in locoregional tumor control rates comparable to historical controls, low toxicity, and little decrement in swallowing function or QOL.
Management of Cytokine Release Syndrome: An Update On Emerging Antigen-Specific T Cell Engaging Immunotherapies
Khadka, Roman H., Johnson, Aaron J. , Sakemura, Reona , Kenderian, Saad S. , Johnson, Aaron J.

Mayo Clinic

Immunotherapy | June 4, 2019 | Volume: 11 | Issue: 10 | Pages: 851-857

10.2217/imt-2019-0074 | PMID 31161844 Get It